Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Rating of “Moderate Buy” from Analysts
Beam Therapeutics INC (NASDAQ: BEAM) has been assigned a rating of "Moderate Buy" by the nine analysts following the company, ...
Tag: BEAM, Analyst Rating
The CFO of Beam Therapeutics Inc. (NASDAQ:BEAM) sells 47,195 shares of stock.
Terry-Ann Burrell, the Chief Financial Officer for Beam Therapeutics Inc. (NASDAQ: BEAM), disclosed on January 18 that she had sold ...